Metabolic & Cardiometabolic
ezetimibe decreases LDL cholesterol (~18-20%)
In plain terms: Does ezetimibe meaningfully lower LDL cholesterol?
Part of: 💊 ezetimibe
Yes — ezetimibe lowers LDL by roughly 15-20% as monotherapy and adds a similar increment on top of a statin, a modest but reliable and well-documented effect.
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: All trials, pooled (Meta-analysis)
How the studies fall
The evidence (12)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Cannon CP, et al. (IMPROVE-IT) 2015 · N Engl J Med | RCT | supports | high | IMPROVE-IT: ezetimibe added to simvastatin in 18,144 post-ACS patients lowered LDL ~24% more (69→54 mg/dL) and cut CV events — outcomes proof it matters. |
| Tellier 2003 · Ann Cardiol Angeiol | meta-analysis | supports | moderate | Pooled data show ezetimibe monotherapy lowers LDL-C by ~19% and adds ~22% incremental LDL-C reduction on top of ongoing statin therapy. |
| Baigent 2011 (SHARP) venue: Lancet · Lancet | RCT | supports | high | SHARP: simvastatin+ezetimibe in 9,270 CKD patients lowered LDL ~0.85 mmol/L and cut major atherosclerotic events 17% — combination benefit. |
| Khan 2019 · J Am Heart Assoc | meta-analysis | supports | high | Network meta-analysis of lipid therapies: ezetimibe add-on gave a consistent extra LDL reduction that tracked with proportional CV risk reduction per mmol/L. |
| Morrone 2012 · Atherosclerosis | meta-analysis | supports | high | Pooled analysis of 27 trials (>21,000 patients): ezetimibe added to statin lowered LDL ~15-20% more than statin alone across statin types and doses. |
| Knopp 2003 · Int J Clin Pract | RCT | supports | high | Pooled phase III monotherapy analysis: ezetimibe 10mg lowered LDL ~18% vs placebo in primary hypercholesterolemia — the pivotal monotherapy magnitude. |
| Blazing 2014 · Am Heart J | RCT | supports | high | In 18,144 post-ACS patients, adding ezetimibe to simvastatin further lowered LDL-C and modestly reduced cardiovascular events versus statin alone. |
| Yasmin 2025 · J Lipid Atheroscler | meta-analysis | supports | high | Meta-analysis of RCTs found moderate-intensity statin plus ezetimibe achieved LDL-C reduction comparable to high-intensity statin monotherapy. |
| Mikhailidis 2011 · Curr Med Res Opin | meta-analysis | supports | high | Meta-analysis: adding ezetimibe to a statin lowered LDL more than doubling/titrating the statin, confirming a consistent ~15-20% incremental effect. |
| Ballantyne 2003 · Circulation | RCT | supports | high | In 628 patients, ezetimibe added to atorvastatin gave an incremental ~12-14% LDL reduction beyond statin alone, roughly equal to tripling the statin dose. |
| Gagné 2002 · Circulation | RCT | supports | moderate | Ezetimibe coadministered with statins lowered LDL a further ~21-25% versus statin plus placebo, including in difficult-to-treat familial hypercholesterolemia. |
| Abbas 2026 · Future Cardiol | meta-analysis | supports | moderate | Systematic review and meta-analysis confirmed pitavastatin-ezetimibe combination produced significantly greater LDL-C lowering than statin monotherapy. |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.